We provide antibodies targeting major respiratory infections that impact global public health, including influenza, the novel coronavirus (SARS-CoV-2), respiratory syncytial virus (RSV), adenovirus, and mycoplasma. Our strengths lie in our extensive lineup of antibodies to satisfy a diverse range of needs, and our stable supply system which is capable of responding to sudden spikes in demand during outbreaks. We rigorously pursue lot-to-lot reproducibility, which is critical to diagnostic performance, thereby supporting rapid and reliable diagnostics in clinical settings worldwide.

​

• Refer to the reactivity list for the reactivity of each product.

• Please submit inquiries here for information on recommended pairs.

• Product lineups are subject to change due to product discontinuations and the development of new products.

​